Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations
Author:
Affiliation:
1. Ematologia Ospedale S. Eugenio - Università Tor Vergata; Roma; Italy
2. Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona; Ancona; Italy
Publisher
Wiley
Subject
Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2012.01814.x/fullpdf
Reference5 articles.
1. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaImmunomodulatory drugs in Myeloma;Quach;Leukemia,2010
2. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement;Dimopoulos;Leukemia,2011
3. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?;Palumbo;Blood Rev,2011
4. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents;Nucci;Clin Infect Dis,2009
5. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide;Offidani;Leuk Lymphoma,2011
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Multiple myeloma and infections in the era of novel treatment modalities;Leukemia Research;2024-08
2. Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay;Hematology, Transfusion and Cell Therapy;2023-10
3. Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America;JCO Global Oncology;2022-07
4. Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China;Frontiers in Oncology;2022-03-17
5. Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper;Critical Reviews in Oncology/Hematology;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3